Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02138136 · ClinicalTrials.gov registry record · Phase 3

Lubiprostone for Children With Constipation

A Phase 3 study of Constipation - Functional, sponsored by Sucampo Pharma Americas.

Completed
Registry status
Phase 3
Development phase
419
Enrollment target
20
Study locations

NCT02138136 is a Phase 3 study of Constipation - Functional that has completed, run by Sucampo Pharma Americas. The registered enrollment target is 419 participants. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02138136, a Phase 3 study of Constipation - Functional, has completed, sponsored by Sucampo Pharma Americas.

COMPLETED
Registry status
Phase 3
Development phase
419 participants
Enrollment target
20
Study locations

Study Summary

This study is for children with constipation. Children who completed 3 months of treatment in the earlier study (NCT02042183): * were invited to participate * will receive lubiprostone for 9 more months * will see if lubiprostone safely relieves their constipation if taken for a whole year

Conditions Studied

Interventions

  • DRUG Lubiprostone

Study Locations (20)

Florida

  • University of Florida - Gainesville
  • Palmetto Professional Research - Hialeah
  • Nemours Children's Clinic - Jacksonville
  • Acevedo Clinical Research Associates - Miami
  • Savin Medical Group Research Center - Miami Lakes
  • Nemours Childrens Clinic - Pensacola

California

  • WCCT Global - Costa Mesa
  • Loma Linda University Health Care - Loma Linda
  • Children's Hospital Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Arizona

  • Arizona Children's Center at Maricopa Medical Center - Phoenix
  • Phoenix Children's Hospital - Phoenix

Arkansas

  • Northwest Arkansas Pediatric Clinic - Fayetteville
  • Arkansas Childrens Hospital Research Institute - Little Rock

Alabama

  • University of South Alabama Women's and Children's Hospital - Mobile

Colorado

  • MCB Clinical Research - Colorado Springs

Delaware

  • Nemours/Alfred I. duPont Hospital for Children - Wilmington

District of Columbia

  • Emmerson Clinical Research - Washington D.C.

Trial Details

FieldValue
Enrollment Target 419 participants
Start Date 2014-02-26
Est. Completion 2017-05-01
Phase Phase 3

Sponsor

Sucampo Pharma Americas

14 total trials

What the Registry Record Tells You About NCT02138136

The ClinicalTrials.gov registry entry for NCT02138136 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Constipation - Functional appearing as the primary indexed condition, and to 1 intervention - of which Lubiprostone is the first listed.

NCT02138136 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT02138136 about?

NCT02138136 is a clinical study titled "Lubiprostone for Children With Constipation". This study is for children with constipation. Children who completed 3 months of treatment in the earlier study (NCT02042183): * were invited to participate * will receive lubiprostone for 9 more months * will see if lubiprostone safely relieves their constipation if taken for a whole year

What is the current status of trial NCT02138136?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2014-02-26. Estimated completion is 2017-05-01.

What conditions does trial NCT02138136 study?

This clinical trial studies the following conditions: Constipation - Functional.

What interventions are being tested in trial NCT02138136?

The interventions under investigation include: Lubiprostone (DRUG).

Who is sponsoring clinical trial NCT02138136?

This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02138136 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.